LIST OF TABLES AND FIGURES a) Each volume shall contain a list of all tables and figures within that volume.
LIST OF TABLES AND FIGURES. Table 1-1 Summary of MVA-NP+M1 Clinical Studies 15 Table 2-1 Treatment Groups and Number of Participants 21 Table 3-1 Schedule of Assessments (Main Cohort) 28 Table 3-2 Schedule of Assessments (Immunogenicity Cohort) 29 Table 7-1 Sample Size Calculations (80% power, two-sided alpha levels) 55 Figure 1-1 Immunogenicity of MVA-NP+M1 in Older Adults (FLU001) 16 Figure 1-2 Area under the Curve Responses for Patricipants Vaccinated using MVA-NP+M1 (1.5 × 108 pfu) Manufactured on AGE1.CR.pIX® and Chicken Embryo Fibroblasts 17 Figure 2-1 Study Flow Diagram 20 Figure 2-2 Follow-up Procedures for the Main Cohort (Participants Vaccinated early in the Influenza Season) 23 Figure 2-3 Follow-up Procedures for the Main Cohort (Participants Vaccinated later in the Influenza Season) 24 Figure 2-4 Follow-up Procedures for the Immunogenicity Cohort (Participants Vaccinated early in the Influenza Season) 25 Figure 2-5 Follow-up Procedures for the Immunogenicity Cohort (Participants Vaccinated later in the Influenza Season) 26 LIST OF ABBREVIATIONS AUC Area under the curve CEF Chicken embryo fibroblasts CRO Contract research organisation DMC Data monitoring committee DMSO Dimethyl sulfoxide EDTA Ethylenediaminetetraacetic acid ELISpot Enzyme linked immunosorbent spot eDiary Electronic diary GMO Genetically modified organism HA/H Haemagglutinin HIV Human immunodeficiency virus ICH GCP International Council on Harmonisation Good Clinical Practice ICS Intracellular cytokine staining IEC Independent ethics committee IFN-γ Interferon gamma ILI Influenza like illness IRB Institutional review board MedDRA Medical dictionary for regulatory activities M1 Matrix 1 MVA Modified vaccinia virus Ankara NA/N Neuraminidase NP Nucleoprotein pfu Plaque forming units QIV Quadrivalent influenza vaccine RT-PCR Reverse transcription polymerase chain reaction SAE Serious adverse event SAP Statistical analysis plan TCID50 Tissue culture infectious dose CONTACTS Sponsor Vaccitech Ltd The Schrodinger Building Xxxxxxx Road The Oxford Science Park Oxford, OX4 4GE UK Tel: +00 (0)0000 000000 Local Medical Monitor Dr Xxxx Xxxxxxx MBChB, FRACP, FRCPC, FAAP Clinical Network Services (CNS) Contract Research Organisation Clinical Network Services Pty Ltd (CRO) Level 4 00 Xxxxxxx Xxxxxx Xxxxxxx Xxxxxxxxxx 4066 Australia Manufacturing Facility Emergent BioSolutions 0000 Xxxx Xxxxxxx Xxxxxx Xxxxxxxxx MD 21224 US Packaging and Labelling Xxxxxx BioServices Woodside Industrial Estate Unit 1 Xxxxxx'x Stortford Hertfo...
LIST OF TABLES AND FIGURES. Figure 1: The CompBioMed Logo (‘standard’ version) 12 Figure 2: The CompBioMed Logo ('header’ version) 12 Figure 3: CompBioMed Slide Tempate 13 Figure 4: The CompBioMed Twitter Account 15 1 Version Log Version Date Released by Nature of Change V1.0 01/12/2016 Xxxx Xxxxxx First Draft V1.1 15/12/2016 Xxxx Xxxxxx Second Draft V1.2 21/12/2016 Xxxxxx Kiri Final Draft 2 Contributors Name Institution Role Xxxx Xxxxxx CBK Sci Con Author Xxxxx X Xxxxxxx UCL Editor Xxxxxx Xx Xxxxxxxxx UPF Editor Xxxxxxx Xxxxxxx BSC Editor Xxxx Xxxx BSC Editor 3 Definition and Acronyms Acronyms Definitions XxX Centre of Excellence WP Work Package KPI Key Performance Indicator HPC High Performance Computing SME Small and Medium Enterprise R&D Research and Development COST European Cooperation in Science and Technology MoU Memorandum of Understanding 4 Executive Summary Computational methods, based on human biology, are now reaching maturity in the biomedical domain, rendering predictive models of health and disease increasingly relevant to clinical practice by providing a personalized aspect to treatment. Computer based modelling and simulation is well established in the physical sciences and engineering, where the use of high performance computing (HPC) is now routine. CompBioMed is a user-driven Centre of Excellence (XxX) in Computational Biomedicine, designed to nurture and promote the uptake and exploitation of high performance computing within the biomedical modelling community. Our user communities come from academia, industry and clinical practice. The CompBioMed Centre of Excellence in Biomedical Computing is distributed in nature, relying on collaboration within the project, and also with external stakeholders. To this end, CompBioMed will develop and coordinate dissemination activities that enable us to engage external stakeholders in academia, healthcare and industry with the activities of the project. The success of CompBioMed relies on its messages, developments, activities, and results being disseminated into the biomedical community, as well as growing and interacting with its user communities. This deliverable, D3.2: Dissemination Action Plan, acts as a detailed and comprehensive report on the dissemination actions that will be carried out by the project. This deliverable is linked to CompBioMed’s Task 3.1: Production of a Dissemination Action Plan, and the release of it is also Milestone 2 in the project. This action plan is a ‘living document’ that will be updated th...
LIST OF TABLES AND FIGURES. I. INTRODUCTION 1 II. THE ERA-ENVHEALTH STRATEGY AND TOOLS FOR DISSEMINATION 1
LIST OF TABLES AND FIGURES. Figure 1 ERA-ENVHEALTH’s dissemination and communication strategy 2 Figure 2 ERA-ENVHEALTH stakeholders 5 Figure 3 Diagram presenting the instruments used by the ERA- ENVHEALTH project to disseminate and communicate its outputs. 9 Table 1 ERA-ENVHEALTH target audiences and different tools in relation to the Communication and Dissemination Strategy 13 Table 2 Scheduled information to be communicated 15 Table 3 Indicators monitored by the project coordinator and WP5 leader to ensure that the dissemination and communication strategy is running in an efficient way. 18
LIST OF TABLES AND FIGURES. Figure 1: New software architecture of the XXXXXX system. Figure 2: Monitoring information. Figure 3: Data recording web interface. Figure 4: DC/DC output configuration. Figure 5: New version of shell design. Front-side view. Figure 6: New version of shell design. Back-side view. Figure 7: Communications architecture. Figure 8: Onboard XXXXXX Robot Power Architecture. Figure 9: Low-Level Communication Architecture
LIST OF TABLES AND FIGURES. Figure.1 Placement of the high-definition camera.
LIST OF TABLES AND FIGURES. Table 1: Key Words Utilized for Systematic Review from 2001 to 2017 Table 2: Questions and Answers from Emergency Department Physician Table 3: Questions and Answers from Private-Practice Dentist in Atlanta #1 Table 4: Questions and Answers from Private-Practice Dentist in Atlanta #2 Table 5: Questions and Answers from Electronic Health Record Software Technology Employee Table 6: Research Questions and Synthesis of Expert Opinions of the Project Figure 1: Nationwide Dental-Related Emergency Department Visits: 2000 to 2012 Figure 2: Dental Insurance Coverage Status: 1996 Figure 3: Dental Insurance Coverage Status: 2010 Figure 4: Data Mapping Via Patient Identifier LIST OF ABBREVIATIONS AND ACRONYMS ACA Affordable Care Act ADA® American Dental Association® ADA® SCDI American Dental Association® Standards Committee on Dental- Informatics ANSI American National Standards Institute ARRA American Recovery and Reinvestment Act CDA® Clinical Document Architecture® CDT Current Dental Terminology CHCS Composite Health Care System CMS Centers for Medicare and Medicaid COHRI Consortium for Oral Health-Related Informatics DICOM® Digital Imaging and Communications in Medicine® DDS Dental Diagnostic System (EZCodes) DoD Department of Defense ED Emergency Department EDR Electronic Dental Record EHR Electronic Health Record EP Eligible Professional FHIR® Fast Healthcare Interoperability Resource® FQHC Federally Qualified Health Center HIPAA Health Insurance Portability and Accountability Act of 1996 HIT Health Information Technology HITECH Health Information Technology for Economic and Clinical Health Act HITSP Health Information Technology Standards Panel HL7® Health Level 7® HL7® V3® HL7 Version 3® HTTPS Hypertext Transfer Protocol ICD International Classification of Diseases IHS Indian Health Service IRB Institutional Review Board IT Information Technology JSON JavaScript Object Notation LOINC® Logical Observation Identifiers Names and Codes® MU Meaningful Use OAuth Open Authorization REST Representational State Transfer ROI Return on Investment RPMS Resource and Patient Management System SDO Standards Development Organization SME Subject Matter Expert SNODENT Systemized Nomenclature of Dentistry SNOMED Systemized Nomenclature of Medicine SNOMED-CT Systemized Nomenclature of Medicine Clinical Terms UCSF University of California San Francisco UTHealth University of Texas Health Science Center at Houston VHA Veteran’s Health Administration VistA Veteran’s Administration ...
LIST OF TABLES AND FIGURES. Tables Table 1. Subject Characteristics… 26 Table 2. Bivariable Linear Regression Evaluating the Association Between Adherence and Clinical and Demographic Predictors 28 Table 3. Bivariable Linear Regression Evaluating the Association of Health Literacy with Clinical and Demographic Variables 29 Table 4. Bivariable Logistic Regression Evaluating the Association of Numerate Status with Clinical and Demographic Variables 30 Table 5. Multivariable Linear Regression of the Association of Adherence with Health Literacy and Numerate status 32 Table 6. Multivariable Linear Regression of the Association of Adherence with Predictor Measures 33 Figures Figure 1. Simple Plot of Adherence and Health Literacy 34 Figure 2. Simple Plot of Adherence and Numeracy Score 35 INTRODUCTION Hemophilia is a chronic bleeding disorder characterized by a deficiency in coagulation factor VIII or IX. Without treatment, the most common complication is bleeding into joints, also known as hemarthrosis, which can lead to irreversible functional impairment and chronic pain. With treatment aimed at replacing the missing clotting factor, bleeding episodes can be minimized and even prevented, which ultimately decreases pain and morbidity and mortality in patients with hemophilia and increases quality of life and physical activity (1, 2). Factor replacement regimens can be prescribed as either prophylaxis or on- demand. The prophylactic regimen is preventative and is administered as regular infusions of factor concentrates 2-3 times a week (3). On-demand factor replacement is when the patient only treats with factor replacement at the time of a bleed. For patients with hemophilia, adherence to factor replacement therapy is important although rather complex. Factor replacement therapy requires administering factor replacement intravenously, maintaining infusion records, planning ahead to ensure adequate factor supplies at home, understanding different medication doses, and communicating with treatment center for bleeds and upcoming procedures. Determinants of adherence to medication regimens for hemophilia, similar to other chronic conditions, can be multifactorial. In chronic illnesses, in addition to reporting on demographic, socioeconomic, and patient-related factors that affect adherence. Some studies looked at health literacy and numeracy and demonstrated low health literacy and low numeracy were barriers to adherence to medication regimens in chronic medical conditions. Health literacy is...
LIST OF TABLES AND FIGURES. Tables Table 1: Participation and Data Collection for Each CBT for Carers Group Delivered Table 2: Mean and Standard Deviation Scores on the 28 Item General Health Questionnaire Table 3: Mean and Standard Deviation Scores on the Clinical Outcomes in Routine Evaluation Outcome Measure (CORE-OM) Table 4: Mean and Standard Deviation Total Score on the Xxxxx Xxxxxx Interview with Clinical Categorisation Figures Figure 1: Mean Score ± SEM on the 28 Item General Health Questionnaire. Figure 2: Percentage of Participants in Each Burden Category Pre- and Post Intervention Abstract This project is a first step in considering the clinical effectiveness of a CBT group for carers of people with dementia. This group has been delivered routinely for the last 7 years, and we examined pre- and post-intervention scores on standardised outcome measures, alongside responses to a structured evaluation questionnaire. We found a statistically significant reduction in scores on the 28 item General Health Questionnaire (GHQ-28) for all clusters except depression. The proportion of participants who met criteria for ‘caseness’ on the GHQ-28 also reduced from pre- to post-intervention indicative of clinically significant change. We observed a significant decrease in mean scores on the Clinical Outcomes in Routine Evaluation Outcome Measure (CORE-OM). In terms of carer burden, total scores on the Xxxxx Xxxxxx Interview dropped significantly and more participants were categorised as experiencing ‘mild to moderate burden’ post- intervention as opposed to ‘moderate to severe’ and ‘severe’ pre-intervention. Regarding the evaluation questionnaire, these data suggest that both the format and content of the group were acceptable for participants. In summary, these data suggest that an 8 week CBT group for carers of people with dementia conducted in routine care may lead to clinically significant change. However, future studies with participants randomly allocated to a control group are needed to confirm clinical effectiveness.
